Text Size

In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects (Juniors)

This study has been completed.
Sponsor:
Information provided by:
Fugeia NV
ClinicalTrials.gov Identifier:
NCT01001949
First received: October 26, 2009
Last updated: NA
Last verified: October 2009
History: No changes posted
  Purpose

The investigational product used in this study is a soft drink containing an arabinoxylan-oligosaccharide (AXOS) preparation extracted from wheat bran (hereafter called Wheat Bran Extract, WBE).

The objective of this study is to analyze the effect of the intake of WBE on various parameters of gastrointestinal health in children (8-12 yrs). Additionally, safety was analyzed using treatment emergent Adverse Events (AEs).


Condition Intervention
Gastrointestinal Health
Healthy Subjects
 Dietary Supplement: Wheat Bran Extract
Dietary Supplement: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects: a Randomized, Placebo-controlled, Double-blind, Cross-over Study

Resource links provided by NLM:

MedlinePlus related topics: Bowel Movement
U.S. FDA Resources

Further study details as provided by Fugeia NV:

Primary Outcome Measures:
  • Bifidobacteria content in feces [ Time Frame: day 19 or 20 of each intervention period ] [ Designated as safety issue: No ]
  • butyric acid content in feces [ Time Frame: day 19 or 20 of each intervention period ] [ Designated as safety issue: No ]
  • stool frequency [ Time Frame: third week of each intervention period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • adverse events [ Time Frame: whole study period ] [ Designated as safety issue: Yes ]

Enrollment: 29
Study Start Date: March 2009
Study Completion Date: October 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Wheat Bran Extract Dietary Supplement: Wheat Bran Extract
soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner
Placebo Comparator: placebo Dietary Supplement: placebo
soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner

  Eligibility

Ages Eligible for Study:   8 Years to 12 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • regular eating habits
  • consent to take in the study product according to the study protocol
  • consent of parents for follow-up of the protocol
  • subject is willing to maintain his/her habitual food and beverage intake throughout the study period (with the exception of omission of prebiotic and probiotic food products as indicated in the study protocol)

Exclusion Criteria:

  • low-calorie diet or other extreme dietary habits in the 6 weeks before the start of the clinical trial
  • recent use of antibiotics
  • abdominal surgery in the past
  • use of medication or dietary supplements known to influence gastrointestinal tract within two weeks of start of clinical trial. Examples of such medication/dietary supplements are antispasmodics, anti-diarrhea medication and/or probiotic medication
  • serious illness within 3 months of start of clinical trial
  • chronic gastrointestinal conditions such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), chronic constipation, history of frequent diarrhea, clinically important lactose intolerance
  • complete anesthetics within 3 month of the start of the clinical trial
  • allergy for wheat products
  • celiac disease
  • Subject has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the subject at undue risk
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01001949

Locations
Belgium
Department of Gastrointestinal Research, Laboratory Digestion and Absorption
Leuven, Belgium, 3000
Sponsors and Collaborators
Fugeia NV
Investigators
Study Director: Willem Broekaert, Ph.D. Fugeia NV
  More Information

No publications provided

Responsible Party: Kristin Verbeke, Ph.D., Katholieke Universiteit Leuven
ClinicalTrials.gov Identifier: NCT01001949     History of Changes
Other Study ID Numbers: ML5282 junior
Study First Received: October 26, 2009
Last Updated: October 26, 2009
Health Authority: Belgium: Institutional Review Board

ClinicalTrials.gov processed this record on June 18, 2013